Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Big Spend-Down: US FDA Eyes $159M Reduction In Carryover User Fees

Executive Summary

Agency will substantially reduce amount of human drug and biosimilar user fees that it carries over from year to year by the end of fiscal 2022; carryover generic drug and biosimilar fees will go toward hiring term-limited employees and building capacity, but a technical issue will keep FDA from accessing $79m in PDUFA fees.

You may also be interested in...



US FDA Exploring Furlough Possibility If User Fee Bill Not Enacted In Time

Furloughs would allow affected FDA staff to remain employed, while a layoffs would require affected workers to be rehired.

US FDA Exploring Furlough Possibility If User Fee Bill Not Enacted In Time

Furloughs would allow affected FDA staff to remain employed, while a layoffs would require affected workers to be rehired.

MDUFA V: US FDA Staff Could See September Lay-Off Notices

The notices normally would go out on 1 August, but unspent user fee funds may be able to sustain work for a few weeks if the program expires.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS122853

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel